{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:00:29Z","timestamp":1789984829828,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T00:00:00Z","timestamp":1379376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00280-013-2282-y","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T14:27:22Z","timestamp":1379341642000},"page":"1043-1053","source":"Crossref","is-referenced-by-count":44,"title":["Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib"],"prefix":"10.1007","volume":"72","author":[{"given":"Aiping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,17]]},"reference":[{"issue":"23","key":"2282_CR1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"issue":"2","key":"2282_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134","journal-title":"N Engl J Med"},{"issue":"2","key":"2282_CR3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124","journal-title":"N Engl J Med"},{"issue":"4","key":"2282_CR4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"9544","key":"2282_CR5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Hilgard P, Gane E, Blanc JF et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329\u20131338","journal-title":"Lancet"},{"key":"2282_CR6","unstructured":"Lou LG, Mi Y, Xu YP, Chengying Xie, Zhao HB (2011) Preclinical antitumor study of famitinib, an orally available multi-targeted kinase inhibitor of VEGFR\/PDGFR\/c-Kit in phase I clinical trials. In Proceedings of the 102 th annual meeting of the American Association for Cancer Research, 2011 Apr 2\u20136. AACR, Orlando, Florida, Abstr3604"},{"issue":"7","key":"2282_CR7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/bph.12047","volume":"168","author":"C Xie","year":"2013","unstructured":"Xie C, Zhou J, Guo Z, Diao X, Gao Z, Zhong D et al (2013) Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 168(7):1687\u20131706","journal-title":"Br J Pharmacol"},{"key":"2282_CR8","unstructured":"http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"issue":"16","key":"2282_CR9","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2003.99.058","volume":"21","author":"GA Omura","year":"2003","unstructured":"Omura GA (2003) Modified Fibonacci search. J Clin Oncol 21(16):3177","journal-title":"J Clin Oncol"},{"issue":"3","key":"2282_CR10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00001813-200603000-00015","volume":"17","author":"CL Bello","year":"2006","unstructured":"Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J et al (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17(3):353\u2013358","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2282_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldoc C, Vera K, Robert C, Lozahic S, Lassau N et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25\u201335","journal-title":"J Clin Oncol"},{"issue":"10","key":"2282_CR12","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jjco\/hyq073","volume":"40","author":"C Yoo","year":"2010","unstructured":"Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS et al (2010) The efficacy and safety of sunitinib in Korean patients with advanced\u00a0renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40(10):980\u2013985","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"2282_CR13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jjco\/hyp146","volume":"40","author":"H Uemura","year":"2010","unstructured":"Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M et al (2010) A Phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40(3):194\u2013202","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 9","key":"2282_CR14","first-page":"abstr851p","volume":"23","author":"S Qin","year":"2012","unstructured":"Qin S, Jin J, Guo J, Wang J, Zhou F, Huang Y et al (2012) A phase IV multicenter study of the efficacy and safety of sunitinib as first-line therapy in Chinese patients with metastatic renal cell carcinoma. Ann Oncol 23(Suppl 9):abstr851p","journal-title":"Ann Oncol"},{"issue":"20","key":"2282_CR15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4143\/crt.2009.41.2.67","volume":"41","author":"MH Hong","year":"2009","unstructured":"Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ et al (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41(20):67\u201372","journal-title":"Cancer Res Treat"},{"issue":"5","key":"2282_CR16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909\u2013918","journal-title":"J Clin Oncol"},{"issue":"2","key":"2282_CR17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Szczylik C, Oudard S, Siebels M et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(2):2271\u20132281","journal-title":"N Engl J Med"},{"issue":"9637","key":"2282_CR18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al (2008) Efficacy of everolimus in advanced\u00a0renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456","journal-title":"Lancet"},{"issue":"11","key":"2282_CR19","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/1078-0432.CCR-11-3137","volume":"18","author":"CK Lee","year":"2012","unstructured":"Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G et al (2012) Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 18(11):3188\u20133196","journal-title":"Clin Cancer Res"},{"issue":"9807","key":"2282_CR20","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931\u20131939","journal-title":"Lancet"},{"issue":"8","key":"2282_CR21","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.25843","volume":"129","author":"S Tariq Mahmood","year":"2011","unstructured":"Tariq Mahmood S, Agresta S, Vigil CE, Rau J, Wimberger P, Sehouli J et al (2011) Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 129(8):1963\u20131969","journal-title":"Int J Cancer"},{"issue":"15s","key":"2282_CR22","doi-asserted-by":"crossref","first-page":"abstr10025","DOI":"10.1200\/jco.2010.28.15_suppl.10025","volume":"28","author":"A Bertuzzi","year":"2010","unstructured":"Bertuzzi A, Stroppa EM, Secondino S, Pedrazzoli P, Zucali P, Quagliuolo P et al (2010) Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy. J Clin Oncol 28(15s):abstr10025","journal-title":"J Clin Oncol"},{"issue":"15s","key":"2282_CR23","doi-asserted-by":"crossref","first-page":"abstr10014","DOI":"10.1200\/jco.2010.28.15_suppl.10014","volume":"28","author":"E Palassini","year":"2010","unstructured":"Palassini E, Stacchiotti S, Negri T, Brich S, Marrari A, Morosi C et al (2010) Sunitinib malate (SM) in alveolar soft sarcoma (ASPS). J Clin Oncol 28(15s):abstr10014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2282_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-012-0235-8","volume":"7","author":"T Neuhaus","year":"2012","unstructured":"Neuhaus T, Luyken J (2012) Long lasting efficacy of Sorafenib in a heavily pretreated patient with thymic carcinoma. Target Oncol 7(4):247\u2013251","journal-title":"Target Oncol"},{"key":"2282_CR25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2407-9-82","volume":"9","author":"LF Kontovinis","year":"2009","unstructured":"Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH et al (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9:82","journal-title":"BMC Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2282-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2282-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2282-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T04:12:22Z","timestamp":1563941542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2282-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,17]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2282-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,17]]}}}